by The global RNA Analysis market size is expected to be worth around US$ 30.48 billion by 2030, according to a new report by Vision Research Reports.
The global RNA Analysis market size was valued at US$ 10.28 billion in 2020 and is anticipated to grow at a CAGR of 14.44% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39075
Growth Factors
Technological advancements in this market can be attributed to the increasing applications of transcriptome sequencing into life science for capturing polyadenylated RNA.
The growing need for analyzing a huge number of genes to understand the gene-to-drug interactions is anticipated to enhance the application of transcriptomics technologies in discovery applications and drug development. For instance, transcriptome profiles of COVID-19 patients have been analyzed to examine the disease prognosis and management. Collaborations between research institutes for the use of transcriptomics in various applications would drive market growth.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 30.48 billion by 2030 |
| Growth Rate | CAGR of 14.44% From 2021 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Technology, Product, Application, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Agilent Technologies; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche AG; Illumina, Inc.;QIAGEN; Thermo Fisher Scientific, Inc; Eurofins Scientific; Merck KGaA; Pacific Bioscience of California, Inc; Affymetrix, Inc; Danaher Corporation; Promega |
By Technology Analysis
Based on technology, real-time-PCR (qPCR) technology dominated the market with the largest revenue share of more than 56% in 2020 due to increased use of PCR for COVID-19 diagnostic across the globe.
The technology is considered to be highly sensitive and quantitative and one of the most suitable methods for interrogating a comparatively small number of transcripts in a broad set of samples. PCR offers relatively high-sensitivity detection of SARS-CoV-2, evaluation of viral RNA in various types of clinical samples, detecting SARS-CoV-2 mutations, and evaluation of anti-SARS-CoV-2 drugs.
The sequencing segment is anticipated to witness substantial growth over the forecast years owing to advancements in the next-generation and SMRT sequencing technology. The presence of several companies providing single-cell RNA sequencing services and the advent of bioinformatics algorithms are also driving the growth of this market.
By Product Analysis
Based on products, the kits & reagents segment accounted for the largest revenue share of over 58% in2020. Rising requirements for high-quality reagents and kits coupled with repeated use of reagents and media in transcriptome studies drive the segment growth.
Growing R&D activities in the pharmaceutical sector and increasing government investments in life science research are the major factors expected to fuel this market for consumables.NGS roots have begun with the adaptation of some SMART cDNA synthesis technology mainly for RNA-sequencing applications.
By Application Analysis
The Infectious diseases and pathogenesis segment accounted for a substantial market share of more than 20% in 2020 and is closely followed by alternative RNA splicing applications. Identification of susceptible cells is crucial for understanding the pathogenic mechanism.
The RNA structure and molecular dynamics segment is expected to expand at a significant CAGR from 2021 to 2028 as pharmaceutical importance for RNA in the development of a new drug is gradually growing.
By End-use Analysis
The government institutes & academic centers segment reported the highest revenue share of over 32% in 2020. The rising adoption of high throughput technologies for the effective process of RNA analysis by government institutes and academic centersis driving the segment growth.
Research in drug discovery is also contributing to the market that is followed by clinical diagnostics. For instance, in April 2021, researchers developed TORNADO-seq, an RNA sequencing-based drug discovery platform to monitor the expression of the large gene for a detailed study of cellular phenotypes in organoids.
The Italian Institute of Technology has signed a partnership agreement with European Molecular Biology Laboratory to expand their collaboration in research. This collaboration is anticipated to strengthen their database and share resources for the study.
By Regional Analysis
North America accounted for the maximum revenue share of more than 46% in 2020. The growth is attributed to the rapid development of structure-based drug designs, increasing focus on transcriptomics research, and high investment in biopharmaceutical research and development.
Growing investments by governments &enterprises are accelerating biotechnology research in Asia Pacific countries. The Japanese government and non-government organizations are highly supportive of the growth of biotechnology research in the country and provide funds to research in the fields of medicine and life sciences.
Increasing focus on Asia Pacific countries is owing to the low-cost manufacturing services, is expected to provide growth opportunities for the manufacturers.
Key Players
- Agilent Technologies, Inc.
- F. Hoffmann-La Roche AG
- Illumina, Inc.
- QIAGEN
- Thermo Fisher Scientific, Inc.
- Eurofins Scientific
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Pacific Bioscience of California, Inc.
- Affymetrix, Inc.
- Danaher Corporation
- Promega
Market Segmentation
- By Technology
- Real Time-PCR (qPCR) Technology
- Microarray Technology
- Sequencing Technology
- Others
- By Product
- Instruments
- Kits & Reagents
- miRNA & siRNA
- Reverse Transcriptases & RT-PCR
- RNA Extraction & Purification
- RNA Interference
- Others
- Services
- By Application
- Construction of RNA Expression Atlas
- Epigenetics
- Infectious Diseases and Pathogenesis
- Alternative RNA Splicing
- RNA Structure & Molecular Dynamics
- Development & Delivery of RNA Therapeutics
- Others
- By End-use
- Government Institutes & Academic Centers
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Hospitals & Clinics
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Italy
- Spain
- France
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
- Saudi Arabia
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Application Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global RNA Analysis Market, By Technology
7.1. RNA Analysis Market, by Technology, 2021-2030
7.1.1. Real Time-PCR (qPCR) Technology
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Microarray Technology
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Sequencing Technology
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Others
7.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global RNA Analysis Market, By Product
8.1. RNA Analysis Market, by Product, 2021-2030
8.1.1. Instruments
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Kits & Reagents
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global RNA Analysis Market, By Application
9.1. RNA Analysis Market, by Application, 2021-2030
9.1.1. Construction of RNA Expression Atlas
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Epigenetics
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Infectious Diseases and Pathogenesis
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Alternative RNA Splicing
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. RNA Structure & Molecular Dynamics
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Development & Delivery of RNA Therapeutics
9.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global RNA Analysis Market, By End-use
10.1. RNA Analysis Market, by End-use, 2021-2030
10.1.1. Government Institutes & Academic Centers
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Pharmaceutical & Biotechnology Companies
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Contract Research Organizations (CROs)
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Hospitals & Clinics
10.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global RNA Analysis Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.2. Market Revenue and Forecast, by Product (2017-2030)
11.1.3. Market Revenue and Forecast, by Application (2017-2030)
11.1.4. Market Revenue and Forecast, by End-use (2017-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Product (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.1.6.2. Market Revenue and Forecast, by Product (2017-2030)
11.1.6.3. Market Revenue and Forecast, by Application (2017-2030)
11.1.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.2. Market Revenue and Forecast, by Product (2017-2030)
11.2.3. Market Revenue and Forecast, by Application (2017-2030)
11.2.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Product (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Product (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Product (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.4. Market Revenue and Forecast, by End-use (2017-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Technology (2017-2030)
11.2.8.2. Market Revenue and Forecast, by Product (2017-2030)
11.2.8.3. Market Revenue and Forecast, by Application (2017-2030)
11.2.8.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.2. Market Revenue and Forecast, by Product (2017-2030)
11.3.3. Market Revenue and Forecast, by Application (2017-2030)
11.3.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Product (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Product (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Product (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.4. Market Revenue and Forecast, by End-use (2017-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Technology (2017-2030)
11.3.8.2. Market Revenue and Forecast, by Product (2017-2030)
11.3.8.3. Market Revenue and Forecast, by Application (2017-2030)
11.3.8.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.2. Market Revenue and Forecast, by Product (2017-2030)
11.4.3. Market Revenue and Forecast, by Application (2017-2030)
11.4.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Product (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Product (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Product (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.4. Market Revenue and Forecast, by End-use (2017-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Technology (2017-2030)
11.4.8.2. Market Revenue and Forecast, by Product (2017-2030)
11.4.8.3. Market Revenue and Forecast, by Application (2017-2030)
11.4.8.4. Market Revenue and Forecast, by End-use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.2. Market Revenue and Forecast, by Product (2017-2030)
11.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Product (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.4. Market Revenue and Forecast, by End-use (2017-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Technology (2017-2030)
11.5.6.2. Market Revenue and Forecast, by Product (2017-2030)
11.5.6.3. Market Revenue and Forecast, by Application (2017-2030)
11.5.6.4. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 12. Company Profiles
12.1. Agilent Technologies, Inc.
12.1.1. Company Overview
12.1.2. Technology Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. F. Hoffmann-La Roche AG
12.2.1. Company Overview
12.2.2. Technology Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Illumina, Inc.
12.3.1. Company Overview
12.3.2. Technology Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. QIAGEN
12.4.1. Company Overview
12.4.2. Technology Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Thermo Fisher Scientific, Inc.
12.5.1. Company Overview
12.5.2. Technology Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Eurofins Scientific
12.6.1. Company Overview
12.6.2. Technology Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck KGaA
12.7.1. Company Overview
12.7.2. Technology Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bio-Rad Laboratories, Inc.
12.8.1. Company Overview
12.8.2. Technology Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Pacific Bioscience of California, Inc.
12.9.1. Company Overview
12.9.2. Technology Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Affymetrix, Inc.
12.10.1. Company Overview
12.10.2. Technology Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39075
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
